About 33% of all drugs in active R&D pipelines are now included in the rare disease category. This categorization presents scientific and operational challenges to sponsors and clinical trial ecosystem participants, the adoption of new strategies, operating models...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
